Trials / Recruiting
RecruitingNCT06484868
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Amryt Pharma · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metreleptin | Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency |
Timeline
- Start date
- 2024-02-08
- Primary completion
- 2028-02-01
- Completion
- 2028-02-01
- First posted
- 2024-07-03
- Last updated
- 2025-07-03
Locations
12 sites across 4 countries: France, Germany, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT06484868. Inclusion in this directory is not an endorsement.